Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Study of the Safety and Bioactivity of AXT-107 in Subjects With Diabetic Macular Edema (DME)

NCT04697758 is registered in ClinicalTrials.gov with AsclepiX Therapeutics, Inc. as lead sponsor.

NCT NCT04697758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04697758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Study of the Safety and Bioactivity of AXT-107 in Subjects With Diabetic Macular Edema (DME)
Lead sponsor
AsclepiX Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
December 10, 2020
Completion date
October 1, 2022
Enrollment
6 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema (dme)